Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.40 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR2B | P41595 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 2/20 | 0.33 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20865831 | 0.80 | HTR2A (0.39) | HTR2CHTR2AHTR2BCA1CA2 | |
| SCHEMBL31607544 | 0.78 | HTR2C (0.40) | HTR2CHTR2AHTR2BCA1CA2 | |
| SCHEMBL5673495 | 0.77 | HTR2C (0.34) | HTR2CHTR2BHTR1DHTR1BALDH1A1 | |
| SCHEMBL14507277 | 0.76 | — | — | |
| SCHEMBL4248733 | 0.75 | HTR2C (0.37) | HTR2CHTR2AHTR2BALDH1A1MAPT | |
| SCHEMBL4478534 | 0.75 | HTR2C (0.37) | HTR2CHTR2AHTR2BALDH1A1MAPT | |
| SCHEMBL13627323 | 0.75 | HTR2C (0.37) | HTR2CHTR2AHTR2BALDH1A1MAPT | |
| SCHEMBL21865764 | 0.70 | PTGS1 (0.33) | HTR2CHTR2AHTR2B | |
| SCHEMBL31607527 | 0.69 | MEN1 (0.58) | HTR2CHTR2AHTR2BCA1CA2 | |
| SCHEMBL5676541 | 0.68 | TRPM2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100230-A1 | Indolin phenylsulfonamide derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| CN-1678581-A | Indolin phenylsulfonamide derivatives | BAYER HEALTHCARE AG (DE) | 2005-10-05 | — | — | CN | disclosed |
| EP-1519919-A1 | INDOLIN PHENYLSULFONAMIDE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004005253-A1 | INDOLIN PHENYLSULFONAMIDE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100230-A1 | Indolin phenylsulfonamide derivatives | PPARD, PPARA, PPARG | HTR2C 456/4885HTR2A 263/4885HTR2B 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.